Table 1.
Combination of bortezomib with other chemotherapeutic agents in relapsed and refractory myeloma
| Study drugs | Phase | Reference | OR% | CR% | PFS (months) |
TTP (months) |
Median OS |
|---|---|---|---|---|---|---|---|
| VD | II | Richardson et al5,6 | PR ≥ 27 | 10 | – | 7 | 17 months |
| Bortezomib or VD | II | Jagannath et al8 | PR ≥ 20; PR ≥ 38 | 11; 4 | – | 7 | 26.8 months |
| Bortezomib vs dexamethasone | III | Richardson et al9 | 38 vs 18 | 6 vs 1 | – | 6.2 vs 3.5 | 80% vs 66% (at 1 year) |
| Bortezomib vs bortezomib plus PEG-doxorubicin | III | Orlowski et al11 | 41 vs 44 | 2 vs 4 | 6.5 vs 9.0 | 6.5 vs 9.3 | 65% vs 76% (at 15 months) |
| VTD vs TD | III | Garderet et al12 | 45 vs 25 | 45 vs 21 | 18.3 vs 13.6 | 19.5 vs 13.8 | 71% vs 65% (at 2 years) |
| Lenalidomide, bortezomib, and dexamethasone | II | Richardson et al13 | 64 | 11 | 9.5 | – | 30 |
| Bortezomib, dexamethasone, and panobinostat vs VD | III | San-Miguel et al38 | 60.7 vs 54.6 | 27.6* vs 16.7 | 11.9 vs 8.08 | – | 33.6 vs 30.4 |
| Panobinostat, bortezomib, and dexamethasone | II | Richardson et al39 | 34.5 | 0 | 5.4 | – | Not reached |
| Vorinostat and bortezomib vs bortezomib | III | Dimopoulus et al37 | 56.2 vs 40.6 | 7.9 vs 5.3 | 7.63 vs 6.83 | 7.73 vs 7.03 | Not reached |
Note:
*
Includes CR and nCR.
Abbreviations: CR, complete response; nCR, near CR; OR, overall response; OS, overall survival; PFS, progression-free survival; PR, partial response; TD, thalidomide and dexamethasone; TTP, time to progression; VD, bortezomib and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone.